Seres Therapeutics Names Thorell Finance Chief as Arkowitz Retires
By Colin Kellaher Seres Therapeutics has hired Marella Thorell as executive vice president and chief financial officer of the microbiome-therapeutics company as current finance chief David Arkowitz r
Evelo Biosciences Shareholders Approve Dissolution Plan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersPhio Pharma (NASDAQ:PHIO) stock increased by 33.9% to $1.5 during Wednesday's pre-market session. The company's market cap stands at $3.6 million. Tenax Therapeutics (NASDAQ:TENX) shares moved
Express News | On December 1, 2023, Evelo Biosciences Was Notified By NASDAQ's Listing Qualifications That As A Result Of The Events Disclosed In Its Filing On November 21, The Staff Believes That The Company No Longer Has An Operating Business And Is Public Shell-8K
US Stocks Mixed; Dow Gains 50 Points
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 35,323.77 while the NASDAQ fell 0.13
Express News | Regarding The Dissolution, Evelo Biosciences' Simba Gill Ceased Serving As The Company's President, CEO And President, And Marella Thorell Ceased Serving As The CFO, Secretary, Treasurer, Principal Financial Officer, And Principal Accounting Officer
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.01%
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersHeron Therapeutics (NASDAQ:HRTX) stock moved upwards by 63.0% to $0.88 during Wednesday's regular session. As of 12:31 EST, Heron Therapeutics's stock is trading at a volume of 15.8 million, wh
12 Health Care Stocks Moving In Monday's Intraday Session
GainersMSP Recovery (NASDAQ:LIFW) shares moved upwards by 481.0% to $15.92 during Monday's regular session. MSP Recovery's stock is trading at a volume of 44.7 million shares as of 12:30 EST. This is
12 Health Care Stocks Moving In Friday's Intraday Session
GainersEvelo Biosciences (NASDAQ:EVLO) stock rose 48.5% to $0.46 during Friday's regular session. Trading volume for Evelo Biosciences's stock is 4.0 million as of 13:30 EST. This is 1695.5% of its av
Top 5 Health Care Stocks That Are Preparing To Pump In November
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Evelo Biosciences, Horizon Technology Finance Sign Forbearance Agreement
By Sabela Ojea Evelo Biosciences and Horizon Technology Finance have entered a forbearance agreement, according to a Securities and Exchange Commission filing. Clinical stage biotechnology company E
Top 4 Health Care Stocks That May Rocket Higher This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAtreca (NASDAQ:BCEL) shares moved upwards by 54.2% to $0.42 during Wednesday's after-market session. This security traded at a volume of 6.3 million shares come close, making up 485.4% of its a
Express News | Evelo Biosciences Shares Are Trading Lower After TD Cowen Downgraded the Stock From Outperform to Market Perform
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
UpgradesAccording to National Bank Financial Inc, the prior rating for Brookfield Infrastructure Partners LP (NYSE:BIP) was changed from Sector Perform to Outperform. Brookfield Infr Partners earned $
Bionano Genomics, Ultragenyx Pharmaceutical Among Healthcare Movers
TD Cowen Downgrades Evelo Biosciences to Market Perform
TD Cowen analyst Joseph Thome downgrades Evelo Biosciences from Outperform to Market Perform.
Evelo Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 10/18/2023 — TD Cowen Downgrades Outperform → Market Perform 07/26/2023 693.65% Morgan Stanley $2 → $10 M
Hold Rating on Evelo Biosciences Amid Unfavorable Outcomes and Strategic Changes: An Analyst Recommendation Report
No Data